MX2010009082A - Activadores de glucocinasa. - Google Patents

Activadores de glucocinasa.

Info

Publication number
MX2010009082A
MX2010009082A MX2010009082A MX2010009082A MX2010009082A MX 2010009082 A MX2010009082 A MX 2010009082A MX 2010009082 A MX2010009082 A MX 2010009082A MX 2010009082 A MX2010009082 A MX 2010009082A MX 2010009082 A MX2010009082 A MX 2010009082A
Authority
MX
Mexico
Prior art keywords
glucokinase activators
glucokinase
activators
nephropathy
neuropathy
Prior art date
Application number
MX2010009082A
Other languages
English (en)
Inventor
Norbert Beier
Johannes Gleitz
Ulrich Emde
Lars Thore Burgdorf
Christine Charon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2010009082A publication Critical patent/MX2010009082A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se relaciona con nuevos compuestos de la fórmula (I) en la que R1, R2, R3, y R4 tienen los significados indicados en la reivindicación 1, que son activadores de glucocinasa y pueden usarse para la prevención y/o el tratamiento de diabetes de tipo 1 y 2, obesidad, neuropatía y/o nefropatía. (Ver fórmula I).
MX2010009082A 2008-02-25 2009-02-02 Activadores de glucocinasa. MX2010009082A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08003356 2008-02-25
PCT/EP2009/000653 WO2009106203A1 (en) 2008-02-25 2009-02-02 Glucokinase activators

Publications (1)

Publication Number Publication Date
MX2010009082A true MX2010009082A (es) 2010-09-07

Family

ID=40445308

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009082A MX2010009082A (es) 2008-02-25 2009-02-02 Activadores de glucocinasa.

Country Status (15)

Country Link
US (1) US20100331338A1 (es)
EP (1) EP2244706B1 (es)
JP (2) JP5559702B2 (es)
KR (1) KR20100124778A (es)
CN (1) CN101959515B (es)
AR (1) AR070475A1 (es)
AU (1) AU2009218861A1 (es)
BR (1) BRPI0907925A2 (es)
CA (1) CA2716599A1 (es)
EA (1) EA201001358A1 (es)
ES (1) ES2581386T3 (es)
IL (1) IL207311A0 (es)
MX (1) MX2010009082A (es)
WO (1) WO2009106203A1 (es)
ZA (1) ZA201006822B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN102834391A (zh) * 2010-03-23 2012-12-19 巴斯夫欧洲公司 防治无脊椎动物害虫的哒嗪化合物
EP3936608A1 (en) 2010-03-31 2022-01-12 The Scripps Research Institute Reprogramming cells
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
JP2013212994A (ja) * 2010-06-22 2013-10-17 Sanwa Kagaku Kenkyusho Co Ltd 新規チオフェンカルボキサミド誘導体及びその医薬用途
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
WO2014180562A1 (en) 2013-05-07 2014-11-13 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of cystic fibrosis
SG11201600891UA (en) 2013-08-08 2016-03-30 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
US9546163B2 (en) 2014-12-23 2017-01-17 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
CN104693168A (zh) * 2015-02-11 2015-06-10 佛山市赛维斯医药科技有限公司 一种腈基噻吩酰胺甲苯类双靶点抑制剂及其用途
CN104693170A (zh) * 2015-02-11 2015-06-10 佛山市赛维斯医药科技有限公司 一类烷氧噻吩酰胺类双靶点抑制剂及其用途
CN106632235A (zh) * 2015-02-11 2017-05-10 佛山市赛维斯医药科技有限公司 一类含甲氧苯基噻吩酰胺类结构的双靶点抑制剂及其用途
CN106699725A (zh) * 2015-02-11 2017-05-24 佛山市赛维斯医药科技有限公司 一类苯基噻吩酰胺类sglt2/sglt1双靶点抑制剂及其用途
GB201712884D0 (en) * 2017-08-11 2017-09-27 King's College London Novel therapeutic compounds
CN110568100B (zh) * 2019-09-12 2022-05-31 江西金水宝制药有限公司 一种米格列奈钙r-异构体的检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2647120A (en) * 1949-12-14 1953-07-28 Du Pont 5-nitro-2-thiophenecarboxamides
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB0028383D0 (en) * 2000-11-21 2001-01-03 Novartis Ag Organic compounds
YU37904A (sh) * 2001-11-09 2006-08-17 Boehringer Ingelheim Pharmaceuticals Inc. Benzimidazoli kao korisni inhibitori proteinske kinaze
CA2472711C (en) * 2002-01-18 2012-03-20 Yamanouchi Pharmaceutical Co., Ltd. 2-acylaminothiazole derivative or salt thereof
JP2003321460A (ja) * 2002-02-28 2003-11-11 Takeda Chem Ind Ltd アゾール化合物
WO2005081954A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
EP2308839B1 (en) * 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
JP2007191461A (ja) * 2005-05-23 2007-08-02 Japan Tobacco Inc ピラゾール化合物及びそれらピラゾール化合物を含んでなる糖尿病治療薬
CN101208089A (zh) * 2005-06-03 2008-06-25 泽农医药公司 氨基噻唑衍生物作为人硬酯酰-CoA去饱和酶抑制剂
JP2008543747A (ja) * 2005-06-11 2008-12-04 アストラゼネカ アクチボラグ Ｄｇａｔ阻害剤としてのオキサジアゾール誘導体
WO2007022258A1 (en) * 2005-08-17 2007-02-22 Schering Corporation Novel high affinity thiophene-based and furan-based kinase ligands
WO2008120744A1 (ja) * 2007-03-30 2008-10-09 Japan Tobacco Inc. ５員環アミド化合物およびその用途

Also Published As

Publication number Publication date
KR20100124778A (ko) 2010-11-29
CN101959515B (zh) 2013-06-12
CA2716599A1 (en) 2009-09-03
EP2244706B1 (en) 2016-04-06
AU2009218861A1 (en) 2009-09-03
JP5559702B2 (ja) 2014-07-23
EP2244706A1 (en) 2010-11-03
EA201001358A1 (ru) 2011-04-29
BRPI0907925A2 (pt) 2015-07-28
WO2009106203A1 (en) 2009-09-03
JP6150762B2 (ja) 2017-06-21
CN101959515A (zh) 2011-01-26
IL207311A0 (en) 2010-12-30
ZA201006822B (en) 2011-05-25
JP2014208665A (ja) 2014-11-06
JP2011513252A (ja) 2011-04-28
AR070475A1 (es) 2010-04-07
US20100331338A1 (en) 2010-12-30
ES2581386T3 (es) 2016-09-05

Similar Documents

Publication Publication Date Title
MX2010009082A (es) Activadores de glucocinasa.
MX2010003759A (es) Derivados de piridina utiles como activadores de glucocinasa.
UA99837C2 (en) N-(pyrazole-3-yl)-benzamide derivatives as glucokinase activators
MX2010007926A (es) Derivados de beta-aminoacidos.
TW200730174A (en) Chemical compounds
TW200714597A (en) Chemical compounds
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
MX2009012708A (es) Derivados de piridazinona.
CL2008001017A1 (es) Compuestos derivados de indol, activadores de glucoquinasa; composicion farmaceutica que los comprende; y su uso para la prevencion o el tratamiento de diabetes u obesidad.
MX2009007180A (es) Agonistas del receptor acoplado a la proteina g de la piperidina.
MX2010010317A (es) Compuestos heterociclicos novedosos y usos de los mismos.
HK1157329A1 (en) Piperidinyl gpcr agonists
MY153727A (en) Pyridazinone derivatives
HK1158192A1 (en) Piperidine gpcr agonists
MY155719A (en) 2-benzylpyridazinone derivatives as met kinase inhibitors
HK1135703A1 (en) Piperidine gpcr agonists
MX2009002241A (es) Compuestos adecuados para usarse en tintas y tintas que tienen esos compuestos.
MY153915A (en) Organic compounds
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2010009536A (es) Amidas de acido 5-oxo-2,3,4,5-tetrahidro-benzo[b]oxepin-4-carboxil ico y amidas de acido 2,3-dihidro-benzo[b]oxepin-4-carboxilico para el tratamiento y la prevension de la diabetes tipo 1 y 2.
MX2009012709A (es) Derivados de arileter-piridazinona.
TW200700358A (en) Organic compounds
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs
MX2010009576A (es) Derivados de quinoxalinona como estimulantes de la secrecion de insulina, metodos para obtenerlos y su uso en el tratamiento de la diabetes.
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists